Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus - Full Text View

Purpose

The primary objective of the study is to confirm the clinical efficacy of epratuzumab in the treatment of subjects with Systemic Lupus Erythematosus (SLE)

Condition	Intervention	Phase
Systemic Lupus Erythematosus	Drug: Epratuzumab Drug: Placebo	Phase 3

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease

Resource links provided by NLM:

MedlinePlus related topics: Lupus

U.S. FDA Resources

Further study details as provided by UCB, Inc.:

Primary Outcome Measures:

The percent of subjects meeting treatment response criteria at Week 48 according to a combined response index [ Time Frame: Week 48 ] [ Designated as safety issue: No ]
The percent of subjects meeting treatment response criteria at Week 48 according to a combined response index

Secondary Outcome Measures:

The percent of subjects meeting treatment response criteria at Week 24 according to a combined response index [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
The percent of subjects meeting treatment response criteria at Week 24 according to a combined response index
The percent of subjects meeting treatment response criteria at Week 12 according to a combined response index [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
The percent of subjects meeting treatment response criteria at Week 12 according to a combined response index
The percent of subjects meeting treatment response criteria at Week 36 according to a combined response index [ Time Frame: Week 36 ] [ Designated as safety issue: No ]
The percent of subjects meeting treatment response criteria at Week 36 according to a combined response index
Change from Baseline in daily corticosteroid dose at week 24 [ Time Frame: Baseline, Week 24 ] [ Designated as safety issue: No ]
Change from Baseline in daily corticosteroid dose at week 24
Change from Baseline in daily corticosteroid dose at week 48 [ Time Frame: Baseline, Week 48 ] [ Designated as safety issue: No ]
Change from Baseline in daily corticosteroid dose at week 48

Estimated Enrollment:	780
Study Start Date:	December 2010
Estimated Study Completion Date:	February 2014
Estimated Primary Completion Date:	January 2014 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Placebo Comparator: Placebo (Weekly infusion) Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles	Drug: Placebo Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
Experimental: Epratuzumab 600 mg per week 600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles	Drug: Epratuzumab 600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
Experimental: Epratuzumab 1200 mg every other week 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles	Drug: Epratuzumab 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles Drug: Placebo Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Positive antinuclear antibodies (ANA) at Screening (Visit 1)
Current clinical diagnosis of Systemic Lupus Erythematosus (SLE) by American College of Rheumatology (ACR) criteria such that at least 4 of the 11 criteria are met
Active moderate to severe SLE activity as demonstrated by the British Isles Lupus Assessment Group Index (BILAG)
Active moderate to severe SLE disease as demonstrated by SLEDAI total score.
On stable SLE treatment regimen, including mandatory corticosteroids and immunosuppressants or antimalarials

Exclusion Criteria:

Subjects who are breastfeeding, pregnant, or plan to become pregnant
Subjects with active, severe SLE disease activity which involves the renal system
Subjects with active, severe, neuropsychiatric SLE, defined as any neuropsychiatric element scoring BILAG level A disease.
Subjects with the evidence of an immunosuppressive state
Subjects who, in the opinion of the investigator, are at a particularly high risk of significant infection
History of malignant cancer, except the following treated cancers: cervical carcinoma in situ, basal cell carcinoma, or dermatological squamous cell carcinoma.
Subjects receiving any live vaccination within the 8 weeks prior to screening (Visit 1).
Subjects with history of infections, including but not limited to concurrent acute or chronic viral hepatitis B or C
Subjects with substance abuse or dependence or other relevant concurrent medical condition
Subjects with history of thromboembolic events within 1 year of screening Visit.
Subjects with significant hematologic abnormalities
Subject has received treatment with other anti- B cell antibodies within 12 months prior to screening (visit 1)
Subject use of oral anticoagulant (not including) nonsteroidal anti-inflammatory drugs (NSAIDs) within 12 weeks prior to screening (Visit 1)
Subject has previously participated in this study or has previously received epratuzumab treatment.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01262365

Contacts

Contact: UCB Clinical Trial Call Center

+1 877 822 9493

Show 146 Study Locations

Sponsors and Collaborators

UCB, Inc.

Investigators

Study Director:

UCb Clinical Trial Call Center

+1 877 822 9493 (UCB)

More Information

No publications provided

Responsible Party:	UCB, Inc.
ClinicalTrials.gov Identifier:	NCT01262365 History of Changes
Other Study ID Numbers:	SL0009, 2010-018563-41
Study First Received:	December 14, 2010
Last Updated:	March 28, 2013
Health Authority:	Australia: Department of Health and Ageing Therapeutic Goods Administration Belgium: Federal Agency for Medicinal Products and Health Products Brazil: National Health Surveillance Agency Bulgaria: Bulgarian Drug Agency Czech Republic: State Institute for Drug Control France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) Germany: Paul-Ehrlich-Institut India: Drugs Controller General of India Israel: Ministry of Health Italy: The Italian Medicines Agency Korea: Food and Drug Administration Mexico: Federal Commission for Sanitary Risks Protection Romania: National Medicines Agency Russia: Ministry of Health of the Russian Federation Spain: Spanish Agency of Medicines Taiwan: Department of Health United Kingdom: Medicines and Healthcare Products Regulatory Agency United States: Food and Drug Administration

Keywords provided by UCB, Inc.:

Lupus
Monoclonal antibody
B-Cell immunotherapy
Epratuzumab

Additional relevant MeSH terms:

Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on May 23, 2013

Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (EMBODY 1)